A Novel Long-acting GDF15 Analog for the Treatment of Obesity

Superior body weight reduction with lesser dosing frequency.

If you are interested in this product, please contact us at BD@drugtimes.cn, we will send the non-confidential deck to you for review.

A Novel Long-acting GDF15 Analog for the Treatment of Obesity

Project ID:BP-20240423-OR-030

Product Brief Summary

  • Product Name: A Novel Long-acting GDF15 Analog for the Treatment of Obesity
  • Modality: Fusion protein
  • Target: GDF15/GFRAL
  • Therapeutic Area: Obesity
  • Current Stage: PCC
  • Rights Available: China/Global Right
  • Collaboration Mode: License out

Obesity is a chronic metabolic disease that can increase the risk of developing several severe comorbidities including Type 2 diabetes, cardiovascular disease, osteoarthritis, sleep apnea, and non-alcoholic fatty liver disease.

Huge Unmet Medical Needs

  • About 650 million people are living with obesity and a lot more living with overweight
  • Only about 2% of the 650 million people are treated with anti-obesity medication (AOM)
  • Current approved medicines either come with serious side effects or need frequent injections, leading to poor adherence and persistence with AOMs
A Novel Long-acting GDF15 Analog for the Treatment of Obesity

MoA: GDF15/GFRAL is a Promising Target for Tackling Obesity

  • Growth differentiation factor 15 (GDF15) binds to its specific receptor GFRAL in the area postrema and nucleus
  • The GDF15-GFRAL complex activates the tyrosine kinase receptor RET, which reduces energy in take and ultimately could lead to weight loss
A Novel Long-acting GDF15 Analog for the Treatment of Obesity

Competitive Landscape

With innovative molecular design, the candidate has the potential to be a monthly dosing AOM

A Novel Long-acting GDF15 Analog for the Treatment of Obesity

Advantages of product:

  • The Candidate is a novel long-acting GDF15 analog for obesity treatment with the potential to achieve once-monthly dosing, differentiating from other once-weekly GDF15 analogs or GLP-1 based AOMs
  • The candidate has better and long-lasting body weight reduction efficacy than reference Fc-GDF15
  • The candidate has superior body weight reduction efficacy to Semaglutide with much lesser dosing frequency in ob/ob mice model

Long-acting Efficacy Proof of Concept

  • Single injection of candidate results in body weight loss lasting for a month in mice model
  • The candidate has better and long-lasting body weight reduction efficacy than reference Fc-GDF15
A Novel Long-acting GDF15 Analog for the Treatment of Obesity

Development Status: IND ready

A Novel Long-acting GDF15 Analog for the Treatment of Obesity

If you are interested in this product, please contact us at BD@drugtimes.cn, we will send the non-confidential deck to you for review.

Thank you very much!

发布者:qi.yang,转载请首先联系contact@drugtimes.cn获得授权

(0)
打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2024年6月24日 14:03
下一篇 2024年6月24日 16:59

相关推荐

公众号
公众号
分享本页
返回顶部